Pharmacokinetic study of bioequivalence of orodispersible phenazepam tablets
I.G. Gordeev1, E.V. Oleneva2, A.A. Globenko3, A.V. Kapashin3 , S.N. Mosolov2
1 City Clinical Hospital No. 15 of the Moscow Department of Public Health, Moscow, Russia
2 National Medical Research Center for Psychiatry and Addictology named after V.P. Serbsky of the Ministry of Public Health of Russian Federation, Moscow, Russia
3 “Valenta Pharm”, Moscow, Russia
Summary: In order to confirm the bioequivalence of the new, orodispersible (ODT) dosage form of the phenazepam® and its traditional oral form, an open randomized study of comparative pharmacokinetics, bioequivalence and safety of these forms in 1mg single dose was conducted in 48 healthy volunteers. The duration of the study period of the drug's pharmacokinetics was 72 hours. The total duration of the study for each volunteer was a maximum of 39 days (collection of information about adverse events, comparative analysis of the safety profiles). The average maximum concentration (Cmax) of the active substance in the blood plasma samples of volunteers when taking the studied ODT drug was reached after 1.95 h (Tmax) (in the range of 0.67 to 4.00 h), and when taking an oral comparison drug-after an average of 2.73 h (in the range of 1.00 to 12.00 h) and was 10.61 ng/ml and 10.34 ng/ml, respectively. The average square area under the pharmacokinetic curve “concentration – time” from the moment of taking the drug to the last blood sample with the determined concentration of the active substance at the point of 72 hours (AUC0–72) was 376.59 h ng/ml when taking the test ODT drug and 378.44 h ng / ml when taking the oral comparison drug. Analysis of the pharmacokinetic curves showed that the confidence intervals calculated for the difference in the mean values of Cmax and AUC0–t in the logarithmic scale with subsequent reverse conversion (Cmax = 1.03 (0.92÷1.15) and AUC0–t = 0.99 (0.88÷1.13), that correspond to the conditions for accepting bioequivalence (0,8÷1,25). There were no significant differences in tolerability profiles.
Contact: info@valentapharm.com
1. Green G. Pharmacopeial Standards for the Subdivision Characteristics of Scored Tablets // Pharmeuropa. – 1998, Des. – Vol. 10, No. 4. – P. 547.
2. San L., Casillas M., Ciudad A., Gilaberte I. Dispergiruemye tabletki olanzapina: obzor effektivnosti i komplaensa (referat) // Psikhiatriya i psikhofarmakoterapiya imeni P.B. Gannushkina. – 2011. – № 4. – S. 51–58.
3. Kozlova Zh.M., Zabolotnaya P.G., Maslova M.N. Bystrodispergiruemye oral'nye sistemy dostavki. // Novaya nauka: ot idei k rezul'tatu. – 2015. – № 2. – S. 75–78.
4. Ghosh T., Pfister W. Drug Delivery to the Oral Cavity. – Boca Raton: Taylor & Francis, 2005. – 414 p.
5. Oleneva E.V., Ryvkin P.V., Ladyzhenskii M.Ya., Mosolov S.N. Orodispergiruemye lekarstvennye formy: vozmozhnosti primeneniya v psikhiatrii // Sovremennaya terapiya psikhicheskikh rasstroistv. – 2018. – № 4. – S. 31–39.
6. Bekker R.A., Bykov Yu.V. Novye vozmozhnosti terapii psikhicheskikh i somaticheskikh zabolevanii s ispol'zovaniem preparata Elitseya® Ku-Tab® (obzor literatury) // Psikhiatriya i psikhofarmakoterapiya. – 2017. – № 19 (4). – S. 51–60.
7. Barrett R, James P, MacLeod K. Oxazepam premedication in neurosurgical patients. The use of a fast-dissolving oral preparation of oxazepam as a pre-operative anxiolytic drug in neurosurgical patients // Anaesthesia. – 1984. – Vol. 39. – P. 429–432.
8. Shirsand B., Suresh S., Swamy P.V. et al. Design and Evaluation of Fast Dissolving Tablets of Clonazepam // Indian J Pharm Sci. – 2008, Nov.–Dec. – Vol. 70 (6). – P. 791–795. – DOI: 10.4103/0250O 474X.49125
9. Abed K.K., Hussein A.A., Ghareeb M.M., Abdulrasool A.A. Formulation and Optimization of Orodispersible Tablets of Diazepam // AAPS Pharm Sci Tech. – 2010. – Vol. 11, No. 1. – P. 356–361.
10. Van de Velde A., Camu F. Efficacy of lorazepam oral fast dissolving drug formulation (FDDF) in anesthesia premedication in adults: a double-blind placebo controlled comparison // Acta Anaesthesiol Belg. – 1988. Vol. 39 (2). – P. 95–100.
11. Damle B., Tarabar S., Kuruganti U. et al. Bio-quivalence of Alprazolam Sublingual Tablet Formulation and Alprazolam Immediate Release Tablet in Healthy Volunteers // Journal of Bioequivalence & Bioavailability. – 2013. – Vol. 5 (4). – P. 149–153.
12. PrIndex (Prescription Index) Monitoring of prescribing physicians. Comcon Pharma. – Available at: http://www.comcon-2.com/default.asp?trID= 284 (accessed May, 12, 2020).
13. Seredenin S.B., Voronina T.A., Neznamov G.G, i dr. Fenazepam: 25 let v meditsinskoi praktike. – M.: Nauka, 2007. – 222 s.
14. Gosudarstvennyi reestr lekarstvennykh sredstv, dannye na oktyabr' 2018. – URL: http://grls.rosminzdrav.ru/grls.aspx?s=fenazepam&m=tn (data obrashcheniya 12.05.2020).
15. GOST R 57679–2017. Lekarstvennye sredstva dlya meditsinskogo primeneniya. Issledovaniya bioekvivalentnosti lekarstvennykh preparatov. Data vvedeniya 01.08.2018.
16. Fuglsang A.A. Sequential Bioequivalence Design with a Potential Ethical Advantage // AAPS J. – 2014. – Vol. 16 (4). – P. 843–846.
17. Aleksandrovskii Yu.A. Rol' trankvilizatorov v lechenii pogranichnykh psikhicheskikh rasstroistv // Psikhiatriya i psikhofarmakoterapiya imeni P.B. Gannushkina. – 2003. – № 3. – S. 94–96.
18. Dubnitskaya E.B., Basov A.M. Primenenie fenazepama pri terapii nevroticheskikh sostoyanii // Zhurnal nevropatologii i psikhiatrii imeni S.S. Korsakova. – 1978. – № 9. – S. 1382–1388.
19. Neznamov G.G. Kliniko-farmakologicheskii analiz deistviya sochetanii psikhotropnykh preparatov u bol'nykh s pogranichnymi sostoyaniyami // Novoe v terapii i organizatsii pomoshchi bol'nym s pogranichnymi nervno-psikhicheskimi rasstroistvami. – M., 1986. – S. 46–50.